Mar 14, 2023 / 12:00PM GMT
Mark Breidenbach - Oppenheimer & Co. Inc. - Analyst
Okay. Hello, everyone. Thanks so much for joining us on day two of Oppenheimer's 33rd Annual Healthcare Conference. My name is Mark Breidenbach. I'm one of the biotech analysts here at Op Co.
Our first presenting company of the morning is Achilles Therapeutics, which is developing a new class of T cell therapy called cNeTs. These are designed to target [conserve] neoantigens in solid tumors. Joining us this morning to walk us through the story is the company's CEO, Iraj Ali. We'll try and leave a few minutes at the end for Q&A. (Operator Instructions) And so with that said, let's dive right into the presentation.
Iraj, the mic is yours.
Iraj Ali - Achilles Therapeutics plc - CEO
Thanks, Mark, and thanks, everybody, for this opportunity to tell you a little bit more about Achilles Therapeutics. I would point you to our forward-looking statements and disclaimers, which is available on our website, to review in your own time.
So jumping into the story and giving you a sense of
Achilles Therapeutics PLC at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers